They are all open label trials … that’s why they were able to tout so many case studies throughout the phase 2 trials so they should have a good idea of what the results will be …. and of course let’s not forget the company has consistently touted claims like the following in most quarterly reports ….
Starpharma’s clinical program for DEP® docetaxel continued to progress well during the quarter, with a total of 74 patients enrolled across the monotherapy and combination arms. Encouraging efficacy signals have been observed, including in heavily pre-treated patients with lung, pancreatic, oesophageal, cholangiocarcinoma and gastric cancers.
In addition, encouraging efficacy signals have been observed in DEP® cabazitaxel treated patients with other cancer types, including platinum resistant ovarian cancer and other hardto-treat cancers such as gastroesophageal cancer. Starpharma is recruiting a number of patients with these cancer types, thus expanding the potential clinical applications for DEP® cabazitaxel.
SPL Price at posting:
13.5¢ Sentiment: None Disclosure: Held
